Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2023-10-29 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's use of idle raised funds to purchase financial products, specifically structured deposits and wealth management products. It includes information about board approvals, amounts, counterparties, risk controls, and investment details. The document is not a financial report like an annual or interim report, nor is it a certification or a brief announcement of a report. It is a regulatory disclosure about capital use and investment activities related to fundraising proceeds. This fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and use of raised capital.
2023-10-29 Chinese
关于使用自有闲置资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It details the authorization, amounts, counterparties, risk controls, and investment specifics of these financial products. The document is a disclosure about financing activities related to the company's capital management, specifically the use of idle funds for short-term investments. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report or Interim Report, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage.
2023-10-29 Chinese
2023年三季度报告（更正后）
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2023 Third Quarter Report" from Sichuan Zitonggong Pharmaceutical Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period ending September 30, 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the nine months and the third quarter of 2023. It also includes management assurances about the accuracy of the report and notes that the report is unaudited. The length of the document (15,000 characters) and the detailed financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-29 Chinese
关于部分募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the delay of certain projects funded by raised capital. It details the background of the fundraising, the use of funds, reasons for project delays, and opinions from the board, supervisory committee, and sponsoring institution. The document does not contain financial statements or detailed financial performance data but focuses on the status and management of capital raised and project progress. It is a regulatory announcement about capital use and project timeline changes, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3226 characters, which is consistent with an announcement rather than a full report.
2023-10-25 Chinese
平安证券股份有限公司关于四川梓橦宫药业股份有限公司部分募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor (Ping An Securities) regarding the delay in certain fundraising investment projects of Sichuan Zitonggong Pharmaceutical Co., Ltd. It discusses the use and management of raised funds, project delays, board and supervisory committee approvals, and compliance with regulatory requirements. The content focuses on the status and management of capital raised through stock issuance, specifically addressing the delay in investment projects funded by these raised funds. This is a typical Capital/Financing Update as it provides an update on the use and management of capital raised by the company, including regulatory compliance and internal approvals. The document is not a full financial report, audit report, or earnings release, nor is it a simple announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-10-25 Chinese
第三届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 24th meeting of the third board of directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on specific agenda items such as approval of the 2023 third quarter report and an extension of a fundraising project timeline. The document does not contain the full quarterly report itself but references that the report was disclosed on the Beijing Stock Exchange information platform. The document is an official announcement of board meeting decisions, specifically about management and board matters, including approval of financial reports and project updates. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1422 characters), and it is not the report itself but a meeting resolution announcement, so it is not an Interim/Quarterly Report (IR).
2023-10-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.